Hematopoietic cell transplantation (also called bone marrow transplantation or stem cell transplantation) is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of stem cell transplantation. Hematopoietic cell transplantation is the most effective treatment for cancer. Other treatments, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.
There are two main types of hematopoietic cell transplantation: autologous and allogeneic. In autologous transplantation, the patient’s own hematopoietic stem cells are removed before high-dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned to the patient. In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup.
Market Dynamics
The increasing organic growth strategies, such as product launches by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in January 2020, Bluebird Bio, Inc., a company providing gene therapy products, announced the launch of ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years of age and older with transfusion-dependent β-thalassemia (TDT) for hematopoietic stem cell (HSC) transplantation in Germany. The full common name for ZYNTEGLO is a genetically modified autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the βA-T87Q-globin gene.
Key features of the study:
- This report provides an in-depth analysis of the global hematopoietic stem cell transplantation (HSCT) market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hematopoietic stem cell transplantation (HSCT) market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global hematopoietic stem cell transplantation (HSCT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematopoietic stem cell transplantation (HSCT) market
Detailed Segmentation:
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market , By Transplant Type:
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Hodgkin lymphoma (HL)
- Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
- Bone Marrow Transplant (BMT)
- Peripheral Blood Stem Cells Transplant (PBSCT)
- Cord Blood Transplant (CBT)
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio, Inc.
- Talaris Therapeutics, Inc.
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
